- Home
- SNAL vs BOLD Comparison
SNAL vs BOLD Comparison
Compare SNAL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNAL | BOLD |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 26.9M |
| IPO Year | 2022 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SNAL | BOLD |
|---|---|---|
| Price | $0.89 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 32.3K | ★ 135.2K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,330,445.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $50.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $1.00 |
| 52 Week High | $3.42 | $3.12 |
Technical Indicators
Market Signals| Indicator | SNAL | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 47.83 |
| Support Level | $0.87 | $1.17 |
| Resistance Level | $0.98 | $1.37 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.20 | 24.00 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.